Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2022 | $10.00 | Buy | B. Riley Securities |
| 8/12/2021 | $20.00 → $15.00 | Buy | HC Wainwright & Co. |
| 6/28/2021 | $25.00 | Overweight | Cantor Fitzgerald |
4 - PDS Biotechnology Corp (0001472091) (Issuer)
4 - PDS Biotechnology Corp (0001472091) (Issuer)
4 - PDS Biotechnology Corp (0001472091) (Issuer)
PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced the appointment of Stephan Toutain, MS, MBA, as Chief Operating Officer (COO), effective as of May 1, 2024. "We are thrilled to welcome Stephan to the PDS Biotech team as Chief Operating Officer. His invaluable experience spans many aspects of the life sciences industry, from drug development to commercialization, providing a wealth of knowledge to our team," said Frank Bedu-Addo, PhD, Pre
PRINCETON, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or "the Company"), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced the appointment of Kirk V. Shepard, M.D., as Chief Medical Officer, effective January 22, 2024. Dr. Shepard succeeds Lauren V. Wood, M.D., who is retiring from the Company after five years in the role. Dr. Wood will continue to be available to PDS Biotech during a handover period to facilitate the transition of the role to Dr. Shepard. "We are please
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that three abstracts on Versamune® HPV (PDS0101) have been accepted for presentation at the 2025 American Society of Clinical Oncology ("ASCO") Annual Meeting, taking place May 30-June 3, 2025, in Chicago, Illinois. Details of the presentation are as follows: Title: VERSATILE-003: A Phase 3, Randomized, Open-label Trial of PDS0101 and Pembrolizumab compared with Pembrolizumab for First-Line Treatment of Patients with HPV16-positive Recurr
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that an abstract submitted by the National Cancer Institute ("NCI") reporting clinical data on PDS01ADC, the Company's IL-12 fused antibody drug conjugate, has been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. Details of the presentatio
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a clinical programs update and reported financial results for the full year ended December 31, 2024. "We are pleased with the progress made over the past year and in recent weeks, culminating with the initiation of our VERSATILE-003 Phase 3 clinical trial evaluati
4 - PDS Biotechnology Corp (0001472091) (Issuer)
4 - PDS Biotechnology Corp (0001472091) (Issuer)
B. Riley Securities initiated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $10.00
HC Wainwright & Co. reiterated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $15.00 from $20.00 previously
Cantor Fitzgerald initiated coverage of PDS Biotechnology with a rating of Overweight and set a new price target of $25.00
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m. Eastern Time. Conference Call Details Date: March 27, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)Webcast Registration: Click HereCall Me™ Registration: Click Here (Available 15 minutes prio
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that it has received the official minutes from its meeting with the U.S. Food and Drug Administration ("FDA") regarding next steps in its planned Phase 3 clinical trial of its Versamune® based investigational immunotherapy designed to stimulate a targeted T cell attack against HPV
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to provide a clinical program update on Thursday, August 1, 2024, at 8:00 a.m. ET. Conference Call DetailsDate: August 1, 2024Time: 8:00 a.m. ET Dial-in: 1-877-704-4453 or 1-201-389-0920 Webcast Registration: Click HereCall Me™ Registration: Click Here (Available 15 minutes prior to call) About PDS BiotechnologyPDS Biotechnology is a late-stage
SC 13G/A - PDS Biotechnology Corp (0001472091) (Subject)
SC 13G - PDS Biotechnology Corp (0001472091) (Subject)
SC 13G/A - PDS Biotechnology Corp (0001472091) (Subject)
8-K - PDS Biotechnology Corp (0001472091) (Filer)
10-K - PDS Biotechnology Corp (0001472091) (Filer)
8-K - PDS Biotechnology Corp (0001472091) (Filer)